Drugs / Filorexant
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02549027 | Nov 2009 → Apr 2010 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 24 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT01554176 | May 2012 → Sep 2013 | major depressive disorder | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT01564459 | Mar 2012 → Apr 2013 | diabetic polyneuropathy | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT01513291 | Feb → Oct 2012 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT01021852 | Nov 2009 → Feb 2011 | insomnia | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Filorexant | “BACKGROUND: Filorexant (MK-6096) is an orexin receptor antagonist; here, we evaluate the efficacy of filorexant in the treatment of insomnia in adults.” PMID 26979830 ↗ Aug 2016 |
| Known as | MK-6096 | “BACKGROUND: Filorexant (MK-6096) is an orexin receptor antagonist; here, we evaluate the efficacy of filorexant in the treatment of insomnia in adults.” PMID 26979830 ↗ Aug 2016 |
| Action | Inhibit | “the orexin receptor antagonist filorexant” PMID 28582570 ↗ Aug 2017 |
| Modality | Small molecule | — CHEMBL2107822 ↗ |
| Route | Oral | “Patients (18 to <65 years) with insomnia received 1 of 4 doses of oral filorexant (2.5, 5, 10, 20mg) once daily at bedtime during one period and matching placebo in the other period.” PMID 26979830 ↗ Aug 2016 |